Mechanism of Action
Target
GABA-A receptor — ligand-gated chloride channel. Benzodiazepines bind the alpha-gamma subunit interface (allosteric site, distinct from the GABA binding site).
Effect
Positive allosteric modulator: increases frequency of chloride channel opening in the presence of GABA. Does not directly open the channel. Requires GABA to be present.
vs. Barbiturates
Barbiturates increase duration of opening and can directly activate at high doses — no GABA required. No ceiling effect. Higher lethality in overdose. Benzodiazepines have a ceiling on receptor activation: safer in isolated overdose.
Pharmacokinetic Spectrum
| Category |
Agents |
Key Feature |
Primary Use |
| Ultra-short | Triazolam | Half-life 1.5–5 hours. Rebound insomnia, amnesia. | Rarely used now |
| Short (LOT) | Lorazepam, Oxazepam, Temazepam | Glucuronidation only. No active metabolites. Predictable offset. | Elderly, hepatic impairment, alcohol withdrawal (when accumulation is a risk) |
| Intermediate | Alprazolam, Clonazepam | Alprazolam: high potency, high dependence risk. Clonazepam: long half-life, once daily dosing feasible. | Panic disorder, seizure syndromes |
| Long-acting | Diazepam, Chlordiazepoxide | Active metabolites extend duration days to weeks. Self-tapering effect. | Alcohol withdrawal (preferred), benzodiazepine taper |
Clinical Indications
Indication
Anxiety Disorders
- Not first-line for chronic anxiety (SSRIs/SNRIs preferred)
- Used adjunctively during antidepressant onset latency (2–4 weeks)
- Alprazolam and clonazepam approved for panic disorder
- Clonazepam preferred: longer half-life reduces inter-dose rebound
Indication
Acute Seizures and Status Epilepticus
- First-line agents for seizure termination
- IV lorazepam: standard hospital treatment (0.1 mg/kg)
- IM midazolam: non-inferior to IV lorazepam in prehospital setting (RAMPART trial); preferred when IV access unavailable
- Always follow with a longer-acting antiseizure agent
Indication
Alcohol Withdrawal
- Agents of choice for alcohol withdrawal syndrome
- Diazepam or chlordiazepoxide preferred: self-tapering long half-life
- LOT agents if hepatic impairment or elderly (accumulation risk)
- Dose by symptom-triggered CIWA-Ar scale
Indication
Procedural Sedation
- Midazolam is the agent of choice
- Short half-life (1.5–2.5 hours), rapid IV onset, reliable amnesia
- Water-soluble: no venous irritation (unlike diazepam in propylene glycol)
- Active metabolite accumulates in renal failure — prolonged sedation in ICU infusions
- Reduce sleep-onset latency and increase total sleep time
- Suppress slow-wave sleep and REM sleep — less restorative architecture
- Rebound insomnia on discontinuation (often worse than baseline)
- CBT-I is first-line; pharmacotherapy short-term only
- Temazepam (LOT agent) most commonly used benzodiazepine for sleep
Flumazenil — Reversal Agent
Mechanism
Competitive antagonist at the benzodiazepine binding site. No intrinsic agonist activity. Reverses benzodiazepine sedation and respiratory depression. Half-life 40–80 minutes — shorter than all benzodiazepines it reverses.
- Reversal of procedural sedation
- Selected benzodiazepine overdose (isolated, known)
- Resedation expected: monitor 1–2 hours after last dose
Contraindication
Dependent Patients
- Precipitates acute withdrawal and seizures in physically dependent patients
- Seizures may be refractory: flumazenil blocks the site needed to treat them
- Chronic use or benzodiazepine-controlled seizures: absolute contraindication
Contraindication
TCA Co-ingestion
- If benzodiazepines were used to control TCA-induced seizures, flumazenil unmasks the seizure risk
- Resulting seizures cannot be treated with benzodiazepines
- Suspected TCA co-ingestion: do not give flumazenil
Key Clinical Warnings
Opioid + Benzodiazepine Combination
Concurrent use produces synergistic respiratory depression greater than either agent alone. This combination carries a boxed warning and is a leading cause of drug overdose deaths. Overdose management must address both drug classes simultaneously: naloxone for opioid component, supportive care (not flumazenil routinely) for benzodiazepine component.